According to the report, The U.S. demand for general anxiety disorder market was valued at USD 3,251 million in 2014 and is expected to generate revenue of USD 3,775 million by end of 2020, growing at a CAGR of 2.4% between 2015 and 2020. General anxiety disorders or generalized anxiety disorders (GAD) usually happen along with other physical or mental illnesses such as alcohol or substance abuse, which might mask anxiety symptoms. In some scenario, these other illnesses treated prior to person respond to treatment for the anxiety disorder.
According to the report, The U.S. demand for general anxiety disorder market was valued at USD 3,251 million in 2014 and is expected to generate revenue of USD 3,775 million by end of 2020, growing at a CAGR of 2.4% between 2015 and 2020.
General anxiety disorder (GAD) is characterized by constant and excessive worrying which is hard to control and lead to considerable impairment or distress. Other psychological symptoms of anxiety include irritability and apprehensiveness, and physical symptoms of anxiety are increased muscular tension and fatigue. Effective treatments for general anxiety disorder are medications and psychotherapy. Psychotherapy includes applied relaxation and cognitive-behavioral therapy among others.
According to anxiety and depression association of America, general anxiety disorder affects 3.1% of the U.S. population or 6.8 million adults, in any given year. U.S. stands for the major regional market for anxiety disorder therapeutics worldwide. Growing geriatric population and rising prevalence of anxiety disorders and depression are some of the key factors to drive the market in the years to come. Currently, U.S. general anxiety disorders market is saturated as a variety of antidepressant drugs are available on prescription for the similar symptom. Presently, general anxiety disorders market is on a decline owing to the weak pipeline of novel drugs, patent expiry of major antidepressants and an increasing number of cheap generic drug variants in the market.
Different therapeutic segments of the general anxiety disorder market include antidepressant, benzodiazepines and other therapeutics. The antidepressant was a major therapeutic segment of general anxiety disorder market and constituted 38.6% share of the total demand in 2014 and is expected to continue its dominance in the market over the forecast period. Numerous kinds of medications employed to treat general anxiety disorder. Antidepressants such as serotonin norepinephrine reuptake inhibitor (SNRI) and selective serotonin reuptake inhibitor (SSRI) classes are the first-line medication treatments. Benzodiazepines (clonazepam, alprazolam, diazepam, and lorazepam) are highly efficient in reducing muscular tension, promoting relaxation and other physical symptoms of anxiety.
General anxiety market is highly competitive in nature owing to the presence of both large and small pharmaceutical companies. Eli Lilly and Company, Sanofi S.A. Forest Laboratories, Inc., Johnson & Johnson H. Lundbeck A/S, Merck & Co., Inc., Pfizer, Inc. are some of the dominant players in the market space.
List of Figures
FIG. 1 Market Research Process
FIG. 2 Market Research Methodology
FIG. 3 U.S. General Anxiety Disorder Market, 2014-2020 (USD Million)
FIG. 4 U.S. General Anxiety Disorder Market Revenue Share, By Therapeutics, 2014 & 2020
FIG. 5 U.S. General Anxiety Disorder Market For Antidepressant, 2014 – 2020 (USD Million)
FIG. 6 Top antidepressant drugs in the U.S. based on revenue in 2011-2012 (in million U.S. dollars)
FIG. 7 U.S. General Anxiety Disorder Market For Benzodiazepines, 2014 – 2020 (USD Million)
FIG. 8 Prescription antianxiety drug use in the past month in the U.S. from 1988 to 2012, by gender
FIG. 9 U.S. General Anxiety Disorder Market For Others Therapeutics, 2014 – 2020 (USD Million)
List of Tables
TABLE 1 U.S. general anxiety disorder market: Snapshot